Precision medicine treatment options in metastatic prostate cancer are expanding rapidly—and while it allows care to be tailored to each patient’s individual needs, it also poses increasingly complex treatment decisions for physicians. Clinical insights gathered through real-world evidence bridge the gap between clinical trials and daily practice, answering critical questions about treatment choices and sequencing.
To support clinicians navigating this complexity, Novartis developed PRECISION (PRostatE Cancer dISease observatION data), a real-world data platform designed to generate actionable insights for providers. Harmonizing data from more than 56,000 patients living with metastatic prostate cancer, it is designed to generate applicable insights throughout the care continuum.
Why the Prostate Cancer Community Needs Real-World Evidence
Real-world evidence – clinical insights based on data from real-world use of medicines – supports rapid evidence generation, a crucial necessity to better navigate a constantly evolving treatment landscape.
“The pace of innovation in prostate cancer is accelerating, and our understanding of how to use novel approaches needs to keep up,” said Liviu Niculescu, Chief Medical Officer, US at Novartis. “PRECISION is designed to learn as fast as the scientific landscape is evolving. By continuously integrating new data streams, we ensure our evidence generation is relevant over the long term.”
With data from more than 2,500 urology practices and 200 medical oncology practices across community and academic settings, this artificial intelligence (AI)-fueled data platform, the most comprehensive in the US, shows how care is delivered–and how those decisions can impact patient outcomes.
How PRECISION Is Reducing Complexity for Urologists and Oncologists
Treating metastatic prostate cancer demands coordinated care from a multi-disciplinary team of urologists, oncologists, and radiation oncologists to determine personalized treatment patterns, sequencing, and patient identification.
Real-world evidence helps fill in gaps on how treatments perform across the diverse patient populations we see in daily practice. PRECISION provides important clinical context which clinicians need to offer shared decision making with their patients.
-Dr. Neal Shore, FACS
PRECISION turns complexity into clarity. The platform’s insights have already been shared in 15 publications accepted at peer-reviewed congresses and journals including at American Society of Clinical Oncology (ASCO), ASCO Genitourinary (GU), American Urological Association (AUA), American Society for Radiation Oncology (ASTRO), and others. These publications help to answer critical questions around treatment patterns and sequencing for metastatic prostate cancer.
"Successful clinical trials are the gold standard for drug regulatory approval with associated reimbursement; importantly, real-world evidence helps fill in gaps on how treatments perform across the diverse patient populations we see in daily practice," explains Dr. Neal Shore, FACS, a uro-oncologist who supported the development of this innovative platform. "PRECISION provides important clinical context which clinicians need to offer shared decision making with their patients."
How AI Technology Can Advance Prostate Cancer Care Through PRECISION
The platform’s AI engine streamlines data extraction to ensure physicians receive accurate, timely insights. AI serves three functions:
- Standardizes: Organizes data from diverse sources into one unified format
- Detects: Identifies patterns across large patient populations
- Accelerates: Reduces the time from data collection to actionable insights
Novartis recognizes it takes more than scientific breakthroughs to improve prostate cancer outcomes—it requires a collective effort across the community. Informed by community and academic practices, Novartis is building a future where every man affected by this disease receives precise, personalized care.
To learn more about our commitment to prostate cancer, visit here.
